Cytochrome P450 (CYP) Enzymes

- Enzyme systems that are responsible for metabolizing most psychotropic medications
- Genetic polymorphism
 - Super Extensive metabolizers (SEM's)
 - Extensive metabolizers (EMs)
 - Poor metabolizers (PMs)
 - Slow metabolizers (SM's)
- Can be induced by specific substrates:
 - phenobarbital, ethanol, and steroids
- Can also be inhibited by various medications that are potent competitive inhibitors of the enzymes:
 - cimetidine and ketoconazole

P450 Enzyme System involved in Psychotropic metabolism

CYP 1A2
CYP 2A6
CYP 2C19
CYP 2D6
CYP 2E1
CYP 3A3/4

Drug metabolism Nicotine metabolism Drug metabolism Drug metabolism Alcohol metabolism

CYP2D6 (Debrisoquin hydroxylase)

Inter-ethnic differences (+)

- Whites: 5%-10% are PMs
- African Americans and Asians: 1%-6% are PM's

At least 9 mutant forms of the enzyme

- 33%-50% of Asian and African EMs are IMs (less active)
 Polymorphism (+)


CYP2D6 Substrates

Antipsychotics-


haloperidol*, reduced haloperidol, perphenazine, phenothiazines*, thioridazine*, olanzapine*, risperidone*, sertindole*

- Antidepressantsamytrptiline*, desipramine, imipramine*, nortryptiline, trazadone, fluoxetine, paroxetine, venlafaxine
- Cardiovascular Agentsencanide, flecanide, propanalol*, metropolol, timolol
- Opiates- codeine*, dextramethorphan, hydrocodone*
 galanthamine

Distribution of CYP2D6 Activity in Caucasian Populations



CYP2D6 Poor Metabolizers




Adapted from Smith 2005

CYP2D6 Metabolic Rates

Metabolic type	Rate of metabolism	Plasma Drug levels	Clinical Effects	
<i>PM</i> Poor metabolizer	No metabolism	Toxic drug levels	Side effects	
<i>EM</i> Extensive metabolizer	Normal metabolism	Normal drug level	Normal response	

Adapted from Smith 2005

Ethnic Variation in CYP2D6 Activity




Histograms of CYP2D6 activity in Chinese and Swedish Caucasians display variations in activity. Although Chinese display lower PM rates, they display lower overall metabolic activity due in part to higher rates of IM's

Debrisoquine/4-hydroxy-debrisoquine metabolic ratio

CYP2D6 Metabolic Rates


	Metabolic type	Rate of metabolism	Plasma Drug levels	Clinical Effects Side effects- higher dose	
	1 ntermediate netabolizer	Slow metabolism	High drug levels		
U	<i>IM</i> Itra netabolizer	Super fast metabolism	Low or no drug level	No response at normal doses	

CYP2D6 Poor & Intermediate Metabolizers



adapted from Smith 2005

Nortriptyline Plasma Levels in Japanese: Impact of CYP2D6 phenotype



CYP2D6 Inhibitors

Antidepressants


- Fluoxetine, paroxetine, moclebemide

Antipsychotics

- Haloperidol, fluphenazine, perphenazine, pimozide, thioridazine
- Antihistamines
 - Diphenhydramine, chlorpheniramine, tripelennamine, promethazine, hydroxyzine, clemastine
 - Terfenadine, astemizole, loratadine
- Misc.
 - Cimetidine, methadone, quinidine, ritanovir, celecoxib


Hamelin et al, 1998; Nicolas, et al, 1999; Werner et al, 2003.

CYP2D6 Ultra Metabolizers



Adapted from Smith 2005

Geographic Origin of IM & UM's



The highest frequency of ultra metabolizers (UM's) are found in north east Africa and the Mediterranean area. High frequencies of intermediate metabolizers (IM's) are found in South west Africa and East Asia (not pictured).

adapted from Smith 2005

CYP2D6 Genotypes

- Poor Metabolizers (PM) are more likely to have higher rates of:
- **EPS**
- **TD**
- venlafaxine cardiovascular toxicity
- longer hospital stay
- intolerant to standard pharmacotherapy
- cost of treatment \$4,000 to\$6,000 per year greater

Ultra Metabolizers (SEM) are more likely to have higher rates of:

- resistant to standard pharmacotherapy
- frequent hospitalizations
- oral opiate addiction
- \blacksquare > 20 cigarettes/ day
- cost of treatment \$4,000 to \$6,000 per year greater

Chou, et al, 2000; Zabrocka, et al, 1999; Reggiani, et al, 2000

CYP2C19 (Mephenytoin hydroxylase)

- Inter-ethnic differences (+)
- Polymorphism (+)
- 2%-10% of whites have little or no activity
- 15%-25% of African American and Asians may be PMs
- The enzyme metabolizes diazepam and several antidepressants

Drugs Metabolized by CYP2C19


Benzodiazepines

- diazepam
- Antidepressants
- imipramine, amitriptyline, clomipramine
- citalopram*, sertraline*

Others


- propranolol, hexobarbital, mephobarbital
- proguanil, omeprazole, S-mephenytoin

Poor Metabolizers (PM) of CYP2C19




adapted from Smith 2005

CYP2C19 Activity and $t_{1/2}$ of Diazepam in Chinese



Qin et al, 1999

Sertraline t_{1/2} and CYP2C19 Phenotype



Wang et al, 2001

CYP1A2 (Phenacetin *O*-deethylase)

- Inter-ethnic differences (-)
- Polymorphism (+)
- 12%-13% of whites, Africans, and Asians having little or no activity of this enzyme
- Highly inducible by
 - charbroiled beef, constituents of tobacco, industrial toxins, and cruciferous vegetables such as cabbage, broccoli, and cauliflower

CYP1A2 Substrates

Antidepressants: amitriptyline, imipramine, fluvoxamine Antipsychotics: clozapine, fluphenazine, haloperidol, olanzapine, thiothixine Misc.: acetaminophen, caffeine, cyclobenzaprine, estradiol, mexiletine, naproxen, ondansetron, propranalol, riluzole, ropivacaine, theophylline, tacrine, zileuton, zolmitriptan

CYP1A2 Inhibitors & Inducers

Inhibitors

 Amiodarone, cimetidine, ciprofloxin, enoxacin, fluvoxamine, furafylline, grepafloxacin, methoxsalen, mibefradil, norfloxacin, perfloxacin, pipemidic acid, ritanovir, ticlopidine, tosufloxacin

Inducers


- Carbamazepine, phenobarbital, phenytoin

CYP3A4 (Nifedipine oxidase)

Inter-ethnic differences:

- Asians have lower enzyme activity than whites, likely due to diet or other environmental factors
- Polymorphism (-) Readily inducible by carbamazepine and steroids, as well as inhibited by dietary compounds such as naringin, an ingredient of grapefruit juice

Nifedipine Metabolism in Asian Indians and British Caucasians



Asians have lower enzyme activity than whites, likely due to diet or other environmental factors

Sowunmi et al, 1995

CYP3A4 Substrates

Antipsychotics

clozapine*, haloperidol*, pimozide, quetiapine, risperidone*, sertindole*, thioridazine*, ziprasidone

Antidepressants/ Mood Stabilizers/ Anticonvulsants

carbamazepine, ethosuximide*, mirtazepine*, nefazadone, remoxapride, sertraline, tiagabine, trazadone*, zonisamide*,

Benzodiazepines/ Sedative Hypnotics

alprazolam, buspirone, clonazepam, diazepam*, midazolam, triazolam, zaleplon, zolpidem

Calcium Channel Blockers/ Cardiovascular Agents

amiodarone, amlodipine, atorvastatin, cerivastatin, diltiazem, felodipine, lercanidipine, lidocaine, lovastatin, nifedipine, nisoldipine, nitrendipine, nimodipine, quinidine, quinine, simvastatin, verapamil

Antibiotics/Antifungals/Immune modulators/Chemotherapy

- clarithromycin, cyclosporine, erthyromycin, dapsone, indinavir, ketaconazole, nelfinavir, saquinavir, ritonavir, taxol*, tamoxifen, vincristine
- alfentanil, astemiazole, chlorpheniramine, cisapride, cocaine, codeine*, estrogens, fentanyl, hydrocortisone, methadone, progesterone, salmeterol, terfenadine, testosterone, sildenafil

Adapted from Smith 2005

CYP3A4 Inhibitors & Inducers

Inhibitors

- fluoxetine, fluvoxamine, nefazadone, norfluoxetine, clozapine, haloperidol
- diltiazem, verapamil, gestodene
- erythromycin, itraconazole, ketoconazole, ritanovir
- grapefruit juice, corn
- Inducers
 - carbamazepine, dexamethasone, felbamate,
 - mesoridazine, oxcarbazepine, phenobarbital, phenytoin,
 - rifampin, topiramate

Genetic Porymorphisms involving Drug Metabolizing Enzymes								
	CYP2D6 (PM)	CYP2C19 (PM)	ACE (PM)	ADH2*2	ALDH2*2	α1-AGP Sv		
US Caucasians	8.7	2.7	52-68	5-20	0	36-44		
Chinese	0.7	5.1	22	92	30	18-47		
Eskimoes	-	5-21	5-59	0	43-45	43		
Navajo	-	-	-	-	2			
Mestizos (Mexico City	/) -	-	-	10	0-4	54		
Cuna (Panama)	0	0	29	-	-	- //		
Caboclos (Brazil)	-	-	-	10	17			

Genetic Polymorphisms Involving Drug Metabolizing Enzymes

Notes:

Numbers reflect frequency of genetic distribution (percentage in population studied)

PM: poor metabolizer phenotype

ACE: acetyltransferase

ADH: alcohol dehydrogenase

ALDH: acetaldehyde dehydrogenase


 α 1-AGP Sv: alpha-1-acid glycoprotein S variant

Mendoza et al 1991; Agarwal, et al 1990

Piperine Containing Supplements


- Piperine the active ingredient in black pepper is a potent inhibitor of CYP1A2 & CYP3A4
- The following food supplements contain piperine and may produce interactions with CYP1A2 metabolized medication
 - Acti-Zyyme, Atkins allergy, Atkins blood pressure, Atkins cholesterol, Atkis Cold & Flu, Atkins dieters advantage, Atkins health care, Atkins memory, Atkins menopause, Beyond calcium, Cognicine, DHEA ultra, Diet metabalo-7, Fat binding protein 6, FAT melt - with gymnenema Sylvestre, Hair nutrients, HDT Andropos D 100, Huperzine A Complex, ImmunActin B, Migra Actin, MultiLogics for Men, MultiLogics for Woman, NFA - 500, One Step, PhenSafe, Reliv Arthaffect, Reliv ProVantage, Shen Min, Shen Min - Puritan's Pride, Thermo-Actives, Tribestrone II, Ultra Chondroitin 600

Smoking and Antipsychotic Response




Percent decrease in serum levels due to CYP1A2 induction via smoking

Simvastatin/Grapefruit Juice



Grapefruit Juice Inhibits the Metabolism of Simvastatin and Saquinavir




Grapefruit juice is a strong inhibitor of CYP3A4. It inhibits the enzyme in the small intestine which allows more drug to be absorbed into the bloodstream.

Drugs reported to show Increases when combined with grapefruit juice include: felodipine, nifedipine, verapamil, terfenadine, ethinylestradiol, midazolam, saquinavir, and cyclosporin A

Lilja et al, 1998, Lown et al, 1997




Effects of Tropical Fruit Juice on In-vitro CYP3A4 Activity




Hidaka et al, Drug Metab Dispos. 2004

Felodipine, & Cabernet Sauvignon




Bailey et al, 2003

Nifedipine Side Effects and Corn



Palma-Aguire, 1999

Diet Variation, Migration & Acculturation Among Mexican American Women




Dixon et al, 2000

Citrus Aurantum Containing Supplements

- Citrus Aurantum which is used in both Chinese and Hispanic herbal medicine has been found ton be a stronger inhibitor of CYP3A4 then Grapefruit juice
- Acutrim Natural A.M., Adrenerlin, Allergia, Allergy Relief, Athletica, Citratherm, Citri-Caps, Citri-Caps Plus, Coldflua, Diet Support Formula, Energiza, Exandra Lean, Fen-Tastic, GlycoLean Manager, GO-lite/fm (Fat Metabolizer), Hepato-C, Herbal Lite, HerbaSlim, Metabosurge, Naturally Herbal Phen, Phen-Free, PhenSafe, Pinnacle Thermophen, Pre, ProLab Stoked, Sharp Thinking, Synadrene, Thermicore, Thermo-Lift (ThermoLift), Thermo-Lift II (ThermoLift II), ThermoSyn, THERMO thin, Trim Fit, Ultra Diet-Phen, UltraAC, UltraAP Activated Pyruvate, Vigrex, Xenadrine RFA-1, Xtra Fuel, Xtreme Trim

Malhotra et al, 2001

Indinavir & St. John's wort



Mean concentration-time of indinavir alone (solid line) and with concomitant St John's wort (dotted line)

Piscitelli et al, 2000

Herb- CYP450 Drug Interactions

Drug-A	Herbal-B	P450	Interaction
Ciprofloxin Enoxacin Pipemidic acid Fluvoxamine	Coffee arabica Llex paullina Yerba mate	1A2 inhibition	Increased conc. B Caffeine toxicity
Theophyline Phenytoin	Piper longum Piper nigum	1A2 inhibition	Increased conc. A
	Licorice	1A2 induction	Decreased conc. A
Quinidine Haloperidol Moclobemide	sparteine in Cytisus scoparius	2D6 inhibition	Increased conc. B Circulatory collapse
Nifedipine Seldane, xanax	grapefruit, corn Panax ginseng Ginkgo biloba	3A4 inhibition	Increased conc. A Increased effects
Cyclosporine	St. John's wort	? Induction	
Digoxin, Indinavir Amitriptyline	Licorice		Decreased conc. A Decreased effects

Adapted from Smith 2005

The Ethnopsychopharmacological Approach:

Assessment

- Cultural formulation for Diagnosis
- Choice of Medication
 - Use medical history, concurrent medications, diet and food supplements / herbals combined with knowledge of enzyme activity in certain ethnic groups

Monitor Patient

- Proceed slowly- Involve family
- If side effects intolerable lower dosage, or choose drug metabolized through different route
- If no response-check compliance, raise dose and monitor levels, add inhibitors, switch drug

Major Teaching Points

- Society has become more ethnically and culturally diverse
- An understanding of cross-cultural perspectives in psychopharmacology has become essential for psychiatrists
- Prescribe therapeutic regimen to be culturally appropriate
- Adhere to the basic principle of rational psychopharmacotherapy, that is, to prescribe the lowest possible dose for the shortest duration, maximizing therapeutic effects while minimizing side effects for every patient from different ethnic and cultural backgrounds
- Apply integrative approach in which biological, ethnic, and cultural diversity are taking into account and treatment is tailored to specific individual characteristics

Which of the following statements are correct?

1. Pharmacogenetic profile can influence both the pharmacokinetics and the pharmacodynamics of a given medication.

2. Pharmacokinetics refers the way in which the body handles drugs. This includes absorption, distribution, metabolism (biotransformation) and excretion (elimination).

3. Pharmacodynamics refers to the effects of a drug on the body such as tissue or receptor sensitivity. This explains some ethnic differences in therapeutic doses/effects and side effects of various psychotropic medications.

Which of the following statements are correct?

1. African Americans presenting with affective disorders are apt to be misdiagnosed or over-diagnosed as having schizophrenia.

2. African Americans tend to receive higher dosages of antipsychotic medications and more long-acting depot forms than whites.

3. African Americans tend to Less likely to receive second-generation antipsychotics or selective serotonin reuptake inhibitors.

Which of the following statements are correct?

1. Hispanic Americans are more apt to focus on somatic complaints in depressed.

2. Hispanic Americans require lower doses (1/2) of antidepressants than whites.

3. Hispanic Americans experience more anticholinergic side effects than whites.

Which of the following statements are correct?

1. Asian Americans tend to present with somatic rather than psychological complaints and seek help from primary care physicians.

2. Asian Americans experience a greater incidence of extrapyramidal side effects (EPS) then whites and African Americans Hispanic Americans require lower doses (1/2) of antidepressants than whites.

3. Asian patients receive lower doses and have higher plasma levels of antipsychotics than whites.

Which of the following ethnic groups has the highest percentage of poor metabolizers (PM) of P450 2D6, the enzyme involved in the metabolism of a large number of psychotropic medications?

A. WhitesB. Hispanic AmericansC. African AmericansD. Asian Americans

- Agarwal DP, Goedde HW. Alcohol metabolism, alcohol intolerance and alcoholism: Biochemical and pharmacogenetic approaches. Berlin: Springer-Verlag; 1990
- Ajir K, Smith M, Lin KM, et al. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology. 129:265-270, 1997
- Alfirevic A, Jorgensen AL, Williamson PR, Chadwick, WD, Park BK, Pirmobamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7: 813, 2006
- Allen JJ, Rack PH, Vaddadi KS. Differences in the effects of clomipramine on English and Asian volunteers: preliminary report on a pilot study. Postgrad Med J. 53(suppl 4):79-86, 1977
- Alonso M, Val E, Rapaport MH. An open-label study of SSRI treatment in depressed Hispanic and non-Hispanic women. J Clin Psychiatry. 58:31, 1997
- Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther. 73:529-37, 2003
- Binder RL, Levy R. Extrapyramidal reactions in Asians. Am J Psychiatry. 138:1243-1244, 1981
- Binder RL, Kazamatusri H, Nishimura T, et al. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry. 144:1494-1496, 1987
- Chou WH, Yan FX, de Leon J, Barnhill J, Rogers T, Cronin M, Pho M, Xiao V, Ryder TB, Liu WW, Teiling C, Wedlund PJ. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol. 20:246-51, 2000
- Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486, 2004
- Collazo Y, Tam R, Sramek JJ, Herrera J: Neuroleptic dosing in Hispanic and Asian inpatients with schizophrenia. Mt. Sinai Journal of Medicine 63:31-313, 1996

- de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics. 46:262-73, 2005
- Dixon LB, Sundquist J, Winkleby M. Differences in energy, nutrient, and food intakes in a US sample of Mexican-American women and men: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 152:548-57, 2000.
- Dolder CR, Lacro JP, Dunn LB, et al: Antipsychotic medication adherence: is there a difference between typical an atypical agents. America Journal of Psychiatry 159:514, 2002
- Edeki T. Clinical importance of genetic polymorphism of drug oxidation. Mt Sinai J Med. 63:291-300, 1996
- Escobar JI, Tuason VB. Antidepressant agents: a cross-cultural study. Psychopharmacol Bll. 16:49-52, 1980
- Fleishaker JC, Phillips JP. Adinazolam pharmacokinetics and behavioral effects following administration of 20-60mg oral doses of its mesylate salt in health volunteers. Psychopharmacol. 99:34-39, 1989
- Gaviria M, Gil AA, Javaid JI. Nortriptyline kinetics in Hispanic and Anglo subjects. J Clin Psychopharmacol. 6:227-231, 1986
- Glazer WM, Morgenstern H, Doucette J. Race and tardive dyskinesia among outpatients at a CMHC. Hosp Community Psychiatry. 45:38-42, 1994
- Ghoneim MM, Korttila MK, Chian CK, et al. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacology and Therapeutics. 29:749-756, 1981
- Gray GE, Pi EH: Ethnicity and Psychotropic Medication Related Movement Disorders. Journal of Practical Psychiatry and Behavioral Health 4:259-264, 1998
- Gonzalez FJ: Human cytochromes P450: problem and prospects. Trends and Pharmacology Science Review, 13:346-352, 1992

- Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J.In vitro characterization of cytochrome
 P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 26:536 9 1998
- Herbeck DM, West JC, Ruditis I, et al: Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatric Service 55:677-684, 2004
- Horrai Y, Nakano M, Ishizaki T, et al. Metoprolol and mephenytoin oxidation polymorphism in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmaco Ther. 46:198-207, 1989
- Jann MW, Lam YWF, Chang W-H. Haloperidol and reduced haloperidol plasma concentrations in different ethnic populations and interindividual variabilities in haloperidol metabolism. In: Lin K-M, Poland RE, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press:133-152, 1993
- Jeste DV, Caligiuri MP, Paulsen JS. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry. 52:756-765, 1995
- Kalow W. Interethnic variation of drug metabolism. Trends Pharmaco Sci Rev.12:102-107,1991
- Karno M, Ross RN, Caper RA. Mental health roles of physicians in a Mexican American community. Community Ment Health J. 5:62-69, 1969
- Kishimoto A, Hollister LE. Nortriptyline kinetics in Japanese and Americans., J Clin Psychopharmacology. 4:171-172, 1984

- Kleinman "A. Patients and Healers in the Context of Culture;: An exploration of the borderland between anthropology, medicine, and psychiatry. Berkeley: University of California Press; 1980
- Kumana CR, Lauder IJ, Chan M, Ko W, Lin HF. Differences in diazepam pharmacokinetics in Chinese and white Caucasians: relation to body lipid stores. Eur J clin Pharmacol. 32:211-215, 1987
- Kuno E, Rothbard AB: Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. American Journal of Psychiatry 159:567-572, 2002
- Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol. 26:753-759, 1984
- Lawson WB: Racial and ethnic factors in psychiatric research. Hospital and Community Psychiatry 37:50-54, 1986
- Lewis PO, Rack PH, Vaddadi KS, et al. Ethnic differences in drug response. Postgrad Med J. 56(suppl 1):46-49, 1980
- Lilja, JJ, Kivisto KT, Neovonen PJ. Grapefruit juice-simvastatin interactions: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther 64: 477-83,1998
- Lin KM, Innui TS, Kleinman A, Womack W. Sociocultural determinants of the help-seeking behavior of patients with mental illness. J Nerv Ment Dis. 170:78-85, 1982

- Lin KM, Finder E: Neuroleptic dosage for Asians. American Journal of Psychiatry 140:490-491, 1983
- Lin KM, Poland RE,, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmaclogy. 8:195-201, 1988
- Lin KM, Lau J, Smith R, et al. Comparison of alprazolam plasma levels and behavioral effects in normal Asian and Caucasian male volunteers. Psychopharmacology. 96:365-369, 1988
- Lin KM, Poland RE, Nuccio I, et al: A longitudinal assessment of haloperidol dose and serum concentrations in Asian and Caucasian schizophrenic patients. American Journal of Psychiatry 146:1307-1311, 1989
- Lin K-M, Poland "RE, Chang S, Chang W-H. Psychopharmacology for the Chinese: cross-ethnic perspectives. In: Lin TY, Tsent WS, Yeh EK, eds. Chinese Societies and Mental Health. Hong Kong: Oxford University Press; 308-314, 1995
- Livingston RL, Zucker DK, Isenberg K, Wetzel RD. Tricyclic antidepressants and delirium. J Clin Psychiatry. 44:173-176, 1983
- Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest. 99(10):2545-53. 1997
- Lu FG, Chien C-P, Heming G, Hinton, L., Soussain, C. Ethnicity and Neuroleptic drug dosage. Poster Presentation, Annual Meeting of the American Psychiatric Association. Chicago, IL., May 12. 1987

- Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 69:14-23, 2001
- Manson SM, Walker RD, Kivlahan DR. Psychiatric assessment and treatment of American Indians and Alaska natives. Hosp. Community Psychiatry 38: 165-173, 1987
- Marcos LR, Cancro R. Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother. 36:505-513, 1982
- Matsuda KT, Cho MC, Lin KM, Smith MW, Young AS, Adams JA. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull.32:253-7, 1996
- Melfi CA, Croghan TW, Hanna MP, et al: Racial variation in antidepressant treatment in a Medicaid population. Journal of Clinical Psychiatry 61:16-21, 2000 Mezzich JE, Raab ES. Depressive symptomatology across the Americas. Arch Gen Psychiatry. 37:818-823, 1980
- Mendoza R, Smith MW, Poland RE, et al: Ethnic psychopharmacology: the hispanic and native American perspective. Psychopharmacol Bull. 27:449-461, 1991
- Mihara K, Suzuki A, Kondo T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 65:291-4, 1999
- Morita S, Shimoda K, Someya T, Yoshimura Y, Kamijima K, Kato N. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol. 20:141-9 2000

- Mucklow JC, Fraser HS, Bulpitt CJ, et al. Environmental factors affecting paracetamol metabolism in London factory and office workers. Br J Clin Pharmacol. 10:67-70, 1980
- Mukherjee MD, Shukla S, Woodle J, Rosen AM, Olarte S. Misdiagnosis of schizophrenia bipolar patients: a multiethnic comparison. Am J Psychiatry. 140:1571-1574, 1983
- Nicolas JM, Whomsley R, Collart P, Roba J. In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines.Chem Biol Interact. 1999 Nov 15;123(1):63-79.
- Palma-Aguirre JA, Nava Rangel J, Hoyo-Vadillo C, Girard-Cuesy ME, Castaneda-Hernandez G, Arteaga-Granados E, De Mucha-Macias R. Influence of Mexican diet on nifedipine pharmacodynamics in healthy volunteers. Proc West Pharmacol Soc. 1994;37:85-6.
- Phillips KA, Mayer ML, Aday LA: Barriers to care among racial/ethnic groups under managed care. Health Affairs 19:65-75, 2000
- Pi EH, Simpson GM, Cooper TB. Pharmacokinetics of desipramine in Caucasian and Asian volunteers. Am J Psychiatry. 143:1174-1176, 1986
- Pi EH, Tran-Johnson TK, Walker NR, et al. Pharmacokinetics of desipramine in Asian and Caucasian volunteers. Psychopharmacol Bull. 25:483-387, 1989
- Pi EH, Tran-Johnson TK, Gray GE, et al. Saliva and plasma desipramine levels in Asian and Caucasian volunteers. Pschopharmacol Bull. 27:281-284, 1991
- Pi EH, Wang AL, Gray GE. Asian/non-Asian transcultural tricyclic antidepressant psychopharmacology: a review. Prog Neuropsychopharmacol Biol Psychiatry. 17:691-702, 1993
- Pi EH, Gray GE: A Cross-cultural perspective on psychopharmacology. Essential Psychopharmacology 2:233-262, 1998

- Pi EH and Simpson GM: Cross-Cultural Psychopharmacology: A Current Clinical Perspective. Journal of Psychiatric Services, 56:31-33, 2005
- Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet. 355:547-8, 2000
- Potkin SB, Shen Y, Pardes H, et al. Haloperidol concentrations elevated in Chinese patients. Psychiatric Research. 12:167-172, 1984
- Price N, Glazer W, Morgenstern H: Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. American Journal of Psychiatry 142:1491-1492, 1985
- Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH. Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther. 66:642-6, 1999
- Ramirez LF. Ethnicity and psychopharmacology in Latin America. Mt Sinai J Med. 63:330-331, 1996
- Raskin A, Thomas H, Crook MA. Antidepressants in black and white inpatients. Arch Gen Psychiatry. 32:643-649, 1975
- Reen RK, Roesch SF, Kiefer F, Wiebel FJ, Singh J. Piperine impairs cytochrome P4501A1 activity by direct interaction with the enzyme and not by down regulation of CYP1A1 gene expression in the rat hepatoma 5L cell line. Biochem Biophys Res Commun. 218:562-9, 1996
- Reggiani K, Vandel P, Haffen E, Sechter D, Bizouard P, Vandel S. Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism Encephale. 26:62-7, 2000

- Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs Mayo Clin Prc. 72:835-847,1997
- Rudorfer MV, Robins E. Amitriptyline overdose: clinical effects on tricyclic antidepressant plasma levels. J Clin Psychiatry. 43:457-460, 1982
- Rudorfer MV, Lane EA, Chang WH, et al. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacology. 17:433-440, 1984
- Rudorfer MV, Lane EA, Potter WZ. Interethnic dissociation between debrisoquine and desipramine hydroxylation. J Clin Pharmacology. 5:89-92, 1985
- Ruiz S, Chu P, Sramek J, Rotavi E, Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia. Mt Sinai J Med. 63:306-309, 1996
- Segal SP, Bola JR, Watson MA: Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Services 47:282-286. 1966
- Sjoqvist F, Borga AO, Dahl M-L, Orme MLE. Fundamentals of clinical pharmacology. In: Speight TM, Holford NHG, eds. Avery's drug Treatment. 4th ed. Auckland: ADIS International 1-73, 1997
- Smith M, Lin K-M, Mendoza R. "Nonbiological" issues affecting psychopharmacology: cultural considerations. In: Lin K-M, Poland "Re, Nakasaki G, eds. Psychopharmacology and Psychobiology of Ethnicity. Washington, DC: American Psychiatric Press. 37-60, 1993
- Smith MW; Etnopsicofarmacologia en América Latina. In Alarcon R, Mazzotti G, Nicolini H (Eds) Psiquiatria 2nd Edición Manual Moderno, México DF 2005

- Sowunmi A, Rashid TJ, Akinyinka OO, Renwick AG. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol. 1995 Nov;40(5):489-93.
- Sramek JJ, Sayles MA, Simpson GM: Neuroleptic dosage for Asians: a failure to replicate. American Journal of Psychiatry 143:5535-536, 1986
- Sramek JJ, Roy S, Ahrens T, et al. prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hosp Community Psychiatry. 42:590-592, 1991
- Strickland TL, Lin K-M, Fu P, Anderson D, Zheng Y. Comparison of lithium ratio between African-American and Caucasian bipolar patients. Biol Psychiatry. 37:325-330, 1995
- Zhou HH, Koshakji RP, Siberstein DJ, Wilkinson GR, Wood AJ. Altered sensitivity to and clearance of propranalol in men of Chinese descent as compared with American Whites. N Engl J Med. 320:565-570, 1989
- Zhou HH, Adedoyin A, Wilkinson GR: Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clinical Pharmacology and Therapeutics. 48:10-17, 1990
- Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet.44:279-304, 2005
- Ziegler VE, Biggs TE. Tricyclic plasma levels-effect of age, race, sex, and smoking. JAMA. 238:2167-2169, 1977 Segal SP, Bola JR, Watson MA: Race, quality of care, and antipsychotic prescribing practices in psychiatric emergency services. Psychiatric Services 47:282-286. 1966